Tissue microarray for high-throughput analysis of gene expression profiles in hepatocellular carcinoma

World Journal of Gastroenterology

Volumn 11, Issue 9, 2005, Pages 1369-1372

  Liu, Kai ^a   Lei, Xue Zhong ^a   Zhao, Lian San ^a   Tang, Hong ^a   Liu, Li ^a   Feng, Ping ^a   Lei, Bing Jun ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

HBcAg; HBsAG; Hepatocellular carcinoma; p21; Rb; Tissue microarray

Indexed keywords

HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; PROTEIN P21; RETINOBLASTOMA PROTEIN;

ANTIGEN EXPRESSION; ARTICLE; CANCER GRADING; CANCER SIZE; CLINICAL ARTICLE; CORRELATION FUNCTION; DISEASE SEVERITY; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER RESECTION; PROTEIN DEPLETION; PROTEIN FUNCTION; TISSUE MICROARRAY;

EID: 15844397971     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i9.1369     Document Type: Article

References (43)

1. Das M, Burge CB, Park E, Colinas J, Pelletier J. Assessment of the total number of human transcription units. Genomics 2001; 77: 71-78
2. Bentley DR. The Human Genome Project-an overview. Med Res Rev 2000; 20: 189-196
3. Nagle RB. New molecular approaches to tissue analysis. J Histochem Cytochem 2001; 49: 1063-1064
4. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest 2000; 80 1943-1949
5. Tang ZY. Hepatocellular carcinoma-cause, treatment and metastasis. World J Gastroenterol 2001; 7: 445-454
6. Wang F, Denison S, Lai JP, Philips LA, Montoya D, Kock N, Schule B, Klein C, Shridhar V, Roberts LR, Smith DI. Parkin gene alterations in hepatocellular carcinoma. Genes Chromosomes Cancer 2004; 40: 85-96
7. Anzola M, Cuevas N, Lopez-Martinez M, Saiz A, Burgos JJ, Martinez de Pancorboa M. P14ARF gene alterations in human hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2004; 16 19-26
8. Okumoto K, Hattori E, Tamura K, Kiso S, Watanabe H, Saito K, Saito T, Togashi H, Kawata S. Possible contribution of circulating transforming growth factor-beta1 to immunity and prognosis in unresectable hepatocellular carcinoma. Liver Int 2004; 24: 21-28
9. Peron JM, Couderc B, Rochaix P, Douin-Echinard V, Asnacios A, Souque A, Voigt JJ, Buscail L, Vinel JP, Favre G. Treatment of murine hepatocellular carcinoma using genetically modified cells to express interleukin-12. J Gastroenterol Hepatol 2004; 19: 388-396
10. Jin Z, Dicker DT, El-Deiry WS. Enhanced sensitivity of G1 arrested human cancer cells suggests a novel therapeutic strategy using a combination of simvastatin and TRAIL. Cell Cycle 2002; 1 82-89
11. Lefevre G, Calipel A, Mouriaux F, Hecquet C, Malecaze F, Mascarelli F. Opposite long-term regulation of c-Myc and p27Kip1 through overactivation of Raf-1 and the MEK/ERK module in proliferating human choroidal melanoma cells. Oncogene 2003; 22: 8813-8822
12. Santoni-Rugiu E, Duro D, Farkas T, Mathiasen IS, Jaattela M, Bartek J, Lukas J. E2F activity is essential for survival of Myc-overexpressing human cancer cells. Oncogene 2002; 21: 6498-6509
13. Agiostratidou G, Derventzi A, Gonos ES. Over-expression of CDKIs p15INK4b, p16INK4a and p21CIP1/WAF1 genes mediate growth arrest in human osteosarcoma cell lines. In Vivo 2001; 15: 443-446
14. Chibazakura T, McGrew SG, Cooper JA, Yoshikawa H, Roberts JM. Regulation of cyclin-dependent kinase activity during mitotic exit and maintenance of genome stability by p21, p27, and p107. Proc Natl Acad Sci USA 2004; 101: 4465-4470
15. Chopin V, Toillon RA, Jouy N, Le Bourhis X. P21(WAF1/CIP1) is dispensable for G1 arrest, but indispensable for apoptosis induced by sodium butyrate in MCF-7 breast cancer cells. Oncogene 2004; 23: 21-29
16. Singh RP, Agarwal C, Agarwal R. Inositol hexaphosphate inhibits growth, and induces G1 arrest and apoptotic death of prostate carcinoma DU145 cells: Modulation of CDKI-CDK-cyclin and pRb-related protein-E2F complexes. Carcinogenesis 2003; 24: 555-563
17. Huss R, Theis S, Deeg HJ. CDK-inhibitor independent cell cycle progression in an experimental haematopoietic stem cell leukaemia despite unaltered Rb-phosphorylation. Br J Cancer 1999; 81: 808-813
18. Sheahan S, Bellamy CO, Treanor L, Harrison DJ, Prost S. Additive effect of p53, p21 and Rb deletion in triple knockout primary hepatocytes. Oncogene 2004; 23: 1489-1497
19. Deeds L, Teodorescu S, Chu M, Yu Q, Chen CY. A p53-independent G1 cell cycle checkpoint induced by the suppression of protein kinase C alpha and theta isoforms. J Biol Chem 2003; 278 39782-39793
20. Strait KA, Dabbas B, Hammond EH, Warnick CT, Iistrup SJ, Ford CD. Cell cycle blockade and differentiation of ovarian cancer cells by the histone deacetylase inhibitor trichostatin A are associated with changes in p21, Rb, and Id proteins. Mol Cancer Ther 2002; 1: 1181-1190
21. Peschiaroli A, Figliola R, Coltella L, Strom A, Valentini A, D'Agnano I, Maione R. MyoD induces apoptosis in the absence of RB function through a p21(WAF1)-dependent relocalization of cyclin/cdk complexes to the nucleus. Oncogene 2002; 21: 8114-8127
22. Ricote M, Alfaro JM, Garcia-Tunon I, Arenas MI, Fraile B, Paniagua R, Royuela M. Control of the annual testicular cycle of the marbled-newt by p53, p21, and Rb gene products. Mol Reprod Dev 2002; 63: 202-209
23. Mal A, Chattopadhyay D, Ghosh MK, Poon RY, Hunter T, Harter ML. p21 and retinoblastoma protein control the absence of DNA replication in terminally differentiated muscle cells. J Cell Biol 2000; 149: 281-292
24. Lavelle D, Chen YH, Hankewych M, Desimone J. Inhibition of myeloma cell growth by all-trans retinoic acid is associated with upregulation of p21WAF1 and dephosphorylation of the retinoblastoma protein. Leuk Lymphoma 1999; 35: 261-268
25. Niketeghad F, Decker HJ, Caselmann WH, Lund P, Geissler F, Dienes HP, Schirmacher P. Frequent genomic imbalances suggest commonly altered tumour genes in human hepatocarcinogenesis. Br J Cancer 2001; 85: 697-704
26. Kondoh N, Wakatsuki T, Hada A, Shuda M, Tanaka K, Arai M, Yamamoto M. Genetic and epigenetic events in human hepatocarcinogenesis. Int J Oncol 2001; 18: 1271-1278
27. Lin YW, Sheu JC, Liu LY, Chen CH, Lee HS, Huang GT, Wang JT, Lee PH, Lu FJ. Loss of heterozygosity at chromosome 13q in hepatocellular carcinoma: Identification of three independent regions. Eur J Cancer 1999; 35: 1730-1734
28. Zhang X, Xu HJ, Murakami Y, Sachse R, Yashima K, Hirohashi S, Hu SX, Benedict WF, Sekiya T. Deletions of chromosome 13q, mutations in Retinoblastoma 1, and retinoblastoma protein state in human hepatocellular carcinoma. Cancer Res 1994; 54: 4177-4182
29. Hui AM, Li X, Makuuchi M, Takayama T, Kubota K. Overexpression and lack of retinoblastoma protein are associated with tumor progression and metastasis in hepatocellular carcinoma. Int J Cancer 1999; 84: 604-608
30. Wang Y, Cui F, Lv Y, Li C, Xu X, Deng C, Wang D, Sun Y, Hu G, Lang Z, Huang C, Yang X. HBsAg and HBx knocked into the p21 locus causes hepatocellular carcinoma in mice. Hepatology 2004; 39: 318-324
31. Zhong S, Chan JY, Yeo W, Tam JS, Johnson PJ. Hepatitis B envelope protein mutants in human hepatocellular carcinoma tissues. J Viral Hepat 1999; 6: 195-202
32. Chen WN, Oon CJ, Moh MC. Detection of hepatitis B virus surface antigen mutants in paraffin-embedded hepatocellular carcinoma tissues. Virus Genes 2000; 20: 263-267
33. Gotsman I, Alper R, Klein A, Rabbani E, Engelhardt D, Ilan Y. Inducing oral immune regulation of hepatitis B virus envelope proteins suppresses the growth of hepatocellular carcinoma in mice. Cancer 2002; 94: 406-414
34. Brechot C, Gozuacik D, Murakami Y, Paterlini-Brechot P. Molecular bases for the development of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Semin Cancer Biol 2000; 10: 211-231
35. Dadke D, Jaganath P, Krishnamurthy S, Chiplunkar S. The detection of HBV antigens and HBx-transcripts in an Indian fibrolamellar carcinoma patient: A case study. Liver 2002; 22: 87-91
36. Jacquemier J, Ginestier C, Charafe-Jauffret E, Bertucci F, Bege T, Geneix J, Birnbaum D. Small but high throughput: How "tissue-microarrays" became a favorite tool for pathologists and scientists. Ann Pathol 2003; 23: 623-632
37. Tzankov A, Zimpfer A, Lugli A, Krugmann J, Went P, Schraml P, Maurer R, Ascani S, Pileri S, Geley S, Dirnhofer S. High-throughput tissue microarray analysis of G1-cyclin alterations in classical Hodgkin's lymphoma indicates overexpression of cyclin E1. J Pathol 2003; 199: 201-207
38. Mobasheri A, Airley R, Foster CS, Schulze-Tanzil G, Shakibaei M. Post-genomic applications of tissue microarrays: Basic research, prognostic oncology, clinical genomics and drug discovery. Histol Histopathol 2004; 19: 325-335
39. Toncheva DI, Zaharieva BM. High-throughput tissue microarray analysis of erbB-2 gene amplification in urinary bladder cancer. A study of Bulgarian patients. Urol Int 2003; 71: 408-411
40. Moskaluk CA, Stoler MH. Agarose mold embedding of cultured cells for tissue microarrays. Diagn Mol Pathol 2002; 11 234-238
41. Andersen CL, Monni O, Wagner U, Kononen J, Barlund M, Bucher C, Haas P, Nocito A, Bissig H, Sauter G, Kallioniemi A. High-throughput copy number analysis of 17q23 in 3520 tissue specimens by fluorescence in situ hybridization to tissue microarrays. Am J Pathol 2002; 161: 73-79
42. Nocito A, Kononen J, Kallioniemi OP, Sauter G. Tissue microarrays (TMAs) for high-throughput molecular pathology research. Int J Cancer 2001; 94: 1-5
43. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4: 844-847